The Elephant’s Tail of VAPP, VDPV in the Polio End Game
DOI:
https://doi.org/10.47203/IJCH.2023.v35i02.001Keywords:
Incidence, Goals, Poliomyelitis, Global Health, WalkingAbstract
A lot have been achieved by the Global Polio Eradication Initiative since 1988 after World Health Assembly passed the resolution to eradicate polio. Today, we have decreased the global polio incidence by 99.9% since GPEIs started working. We still have to remove polio from the few leftover pockets and get rid of the final 0.1% of polio cases. We have gained in positive terms that an estimated 16 million people today are walking and more than 1.5 million are alive because of the stakeholders’ strong, strategic and cooperative action. The journey to the last mile has some different difficulties and this article tries to provide additional insights into the strategies to achieve our goal of Polio eradication.
Downloads
References
The Global Polio Eradication Initiative, GPEI , Mission document available online at https://polioeradication.org/ who-we-are/our-mission/ last accessed on 01/03/23.
VAPP and VDPV FAQs and details. CDC Atlanta USA available at https://www.cdc.gov/vaccines/vpd/polio/hcp/vaccine- derived-poliovirus-faq.html . Last accessed last on 07/03/2023.
Vaccine-Associated Paralytic Polio. CDC Atlanta USA available at https://polioeradication.org/global-cvdpv-resource- documents/ . Last accessed last on 15/03/2023
Circulating vaccine-derived polioviruses-Global update, A new approach to control cVDPV2. Resource document from GPEI site https://polioeradication.org/global-cvdpv-resource- documents/ accessed last on 07/03/2023
Vaccine-derived Polioviruses: Managing the risks available online from https://polioeradication.org/tools-and-library/ current-research-areas/vaccine-derived-polioviruses/ , last accessed last on 07/03/2023
Shahmahmoodi S, Mamishi S, Aghamohammadi A, Aghazadeh N, Tabatabaie H, Goya MM, et al. Vaccine-associated paralytic poliomyelitis in immunodeficient children, Iran, 1995–2008. Emerg Infect Dis. 2010 Jul. http://dx.doi.org/10.3201/ eid1607.091606
cVDPV2 Outbreaks and the Type 2 Novel Oral Polio Vaccine (nOPV2) Fact Sheet from the GPEI , PDF
Polio Eradication Strategy 2022–2026: Executive summary. Geneva: World Health Organization; 2021. Licence CC BY-NC-SA 3.0 IGO.
Statement of the thirty-fourth Polio IHR Emergency Committee, 2 February 2023 Statement, available online at https://www. who.int/news/item/02-02-2023-statement-of-the-thirty- fourth-polio-ihr-emergency-committee last accessed on 16/03/2023
Rahnuma Wahid, Laina D Mercer, Tirza De Leon et al. Genetic and phenotypic stability of poliovirus shed from infants who received novel type 2 or Sabin type 2 oral poliovirus vaccines in Panama: an analysis of two clinical trials. The Lancet Microbe. Volume 3, ISSUE 12, e912-e921, December 2022, DOI: https://doi.org/10.1016/S2666-5247(22)00254-3
Implementation of novel oral polio vaccine type 2 (nOPV2) for circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreak response: technical guidance for countries Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA
0 IGO.
Polio Vaccine – Novel Oral (nOPV) Monovalent type 2 available online at https://extranet.who.int/pqweb/vaccines/polio- vaccine-novel-oral-nopv-monovalent-type-2 , last accessed last on 07/03/2023.
The Global Polio Eradication Initiative, GPEI – Reaching every last child, official website available online at https:// polioeradication.org/ last accessed last on 15/03/2023
Downloads
Published
How to Cite
License
Copyright (c) 2023 Abhishek Tiwari, Dr. Shivendra Kumar Singh, Dr. Manish Manar, Dr. Prashant Kumar Bajpai
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
